Thomas P. O'neil - Net Worth and Insider Trading

Thomas P. O'neil Net Worth

The estimated net worth of Thomas P. O'neil is at least $0 dollars as of 2024-11-10. Thomas P. O'neil is the CFO of Protagonist Therapeutics Inc and owns about 0 shares of Protagonist Therapeutics Inc (PTGX) stock worth over $0. Thomas P. O'neil is also the CFO of Satsuma Pharmaceuticals Inc and owns about 0 shares of Satsuma Pharmaceuticals Inc (STSA) stock worth over $0. Details can be seen in Thomas P. O'neil's Latest Holdings Summary section.

Disclaimer: The insider information is derived from SEC filings. The estimated net worth is based on the final shares held after open market or private purchases and sales of common stock with a transaction code of "P" or "S" on Form 4, assuming that Thomas P. O'neil has not made any transactions after 2020-09-01 and currently still holds the listed stock(s). Please note that this estimate may not reflect the actual net worth.

Transaction Summary of Thomas P. O'neil

Thomas P. O'neil Insider Ownership Reports

Based on ownership reports from SEC filings, as the reporting owner, Thomas P. O'neil owns 3 companies in total, including Protagonist Therapeutics Inc (PTGX) , Arcadia Biosciences Inc (RKDA) , and Satsuma Pharmaceuticals Inc (STSA) .

Click here to see the complete history of Thomas P. O'neil’s form 4 insider trades.

Insider Ownership Summary of Thomas P. O'neil

Ticker	Comapny	Transaction Date	Type of Owner
PTGX	Protagonist Therapeutics Inc	2017-12-18	Chief Financial Officer
RKDA	Arcadia Biosciences Inc	2015-05-14	Chief Financial Officer
STSA	Satsuma Pharmaceuticals Inc	2020-09-01	Chief Financial Officer

Thomas P. O'neil Latest Holdings Summary

Thomas P. O'neil currently owns a total of 2 stocks. Among these stocks, Thomas P. O'neil owns 0 shares of Protagonist Therapeutics Inc (PTGX) as of December 18, 2017, with a value of $0 . Thomas P. O'neil also owns 0 shares of Satsuma Pharmaceuticals Inc (STSA) as of September 1, 2020, with a value of $0 .

Latest Holdings of Thomas P. O'neil

Ticker	Comapny	Latest Transaction Date	Shares Owned	Current Price ($)	Current Value ($)
PTGX	Protagonist Therapeutics Inc	2017-12-18	0	46.23	0
STSA	Satsuma Pharmaceuticals Inc	2020-09-01	0	1.10	0

Holding Weightings of Thomas P. O'neil

Thomas P. O'neil Form 4 Trading Tracker

According to the SEC Form 4 filings, Thomas P. O'neil has made a total of 0 transactions in Protagonist Therapeutics Inc (PTGX) over the past 5 years. The most-recent trade in Protagonist Therapeutics Inc is the sale of 8,000 shares on December 18, 2017, which brought Thomas P. O'neil around $160,000.

According to the SEC Form 4 filings, Thomas P. O'neil has made a total of 7 transactions in Satsuma Pharmaceuticals Inc (STSA) over the past 5 years, including 0 buys and 7 sells. The most-recent trade in Satsuma Pharmaceuticals Inc is the sale of 750 shares on September 1, 2020, which brought Thomas P. O'neil around $16,643.

Insider Trading History of Thomas P. O'neil

No transactions are available. GuruFocus only tracks and displays the purchase and sale of non-derivative security in open market or private transactions from SEC filings with the transaction code of P or S.

Total 0

Only the transactions in Open Market or Private Sale at the market prices are included. Other transactions such as conversion of derivative security or exercise of options are not included. Insiders are limited to only officers and/or directors of the company.

Thomas P. O'neil Trading Performance

Please note GuruFocus will not track the insiders’ transaction performance if he/she does not have buying transactions.

Thomas P. O'neil Ownership Network

Ownership Network List of Thomas P. O'neil

No Data

Ownership Network Relation of Thomas P. O'neil

Thomas P. O'neil Owned Company Details

What does Protagonist Therapeutics Inc do?

Who are the key executives at Protagonist Therapeutics Inc?

Thomas P. O'neil is the Chief Financial Officer of Protagonist Therapeutics Inc. Other key executives at Protagonist Therapeutics Inc include Chief Financial Officer Asif Ali , director & President and CEO Patel Dinesh V Ph D , and Chief Development Officer Suneel Gupta .

Protagonist Therapeutics Inc (PTGX) Insider Trades Summary

Over the past 18 months, Thomas P. O'neil made no insider transaction in Protagonist Therapeutics Inc (PTGX). Other recent insider transactions involving Protagonist Therapeutics Inc (PTGX) include a net sale of 165,000 shares made by Patel Dinesh V Ph D , a net sale of 36,975 shares made by William D. Waddill , and a net sale of 39,624 shares made by Asif Ali .

In summary, during the past 3 months, insiders sold 22,203 shares of Protagonist Therapeutics Inc (PTGX) in total and bought 0 shares, with a net sale of 22,203 shares. During the past 18 months, 248,447 shares of Protagonist Therapeutics Inc (PTGX) were sold and 0 shares were bought by its insiders, resulting in a net sale of 248,447 shares.

Protagonist Therapeutics Inc (PTGX)'s detailed insider trading history can be found in Insider Trading Tracker table.

Protagonist Therapeutics Inc Insider Transactions

No Available Data

What does Arcadia Biosciences Inc do?

Who are the key executives at Arcadia Biosciences Inc?

Thomas P. O'neil is the Chief Financial Officer of Arcadia Biosciences Inc. Other key executives at Arcadia Biosciences Inc include Chief Financial Officer Thomas J. Schaefer , Chief Executive Officer Stanley Jr Jacot , and Chief Financial Officer Pamela Haley .

Arcadia Biosciences Inc (RKDA) Insider Trades Summary

Over the past 18 months, Thomas P. O'neil made no insider transaction in Arcadia Biosciences Inc (RKDA). Other recent insider transactions involving Arcadia Biosciences Inc (RKDA) include a net purchase of 2,049 shares made by Thomas J. Schaefer , a net purchase of 5,000 shares made by Stanley Jr Jacot , and a net purchase of 700 shares made by .

In summary, during the past 3 months, insiders sold 0 shares of Arcadia Biosciences Inc (RKDA) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Arcadia Biosciences Inc (RKDA) were sold and 7,749 shares were bought by its insiders, resulting in a net purchase of 7,749 shares.

Arcadia Biosciences Inc (RKDA)'s detailed insider trading history can be found in Insider Trading Tracker table.

Arcadia Biosciences Inc Insider Transactions

No Available Data

What does Satsuma Pharmaceuticals Inc do?

Who are the key executives at Satsuma Pharmaceuticals Inc?

Thomas P. O'neil is the Chief Financial Officer of Satsuma Pharmaceuticals Inc. Other key executives at Satsuma Pharmaceuticals Inc include 10 percent owner Shin Nippon Biomedical Laboratories, Ltd. , director & 10 percent owner Ken Takanashi , and 10 percent owner Braden Michael Leonard .

Satsuma Pharmaceuticals Inc (STSA) Insider Trades Summary

Over the past 18 months, Thomas P. O'neil made no insider transaction in Satsuma Pharmaceuticals Inc (STSA). Other recent insider transactions involving Satsuma Pharmaceuticals Inc (STSA) include a net purchase of 30,477,313 shares made by Shin Nippon Biomedical Laboratories, Ltd. , and a net purchase of 22,053,581 shares made by Ken Takanashi .

In summary, during the past 3 months, insiders sold 0 shares of Satsuma Pharmaceuticals Inc (STSA) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Satsuma Pharmaceuticals Inc (STSA) were sold and 52,530,894 shares were bought by its insiders, resulting in a net purchase of 52,530,894 shares.

Satsuma Pharmaceuticals Inc (STSA)'s detailed insider trading history can be found in Insider Trading Tracker table.

Satsuma Pharmaceuticals Inc Insider Transactions

No Available Data

Thomas P. O'neil Mailing Address

Above is the net worth, insider trading, and ownership report for Thomas P. O'neil. You might contact Thomas P. O'neil via mailing address: Satsuma Pharmaceuticals, Inc., 400 Oyster Point Boulevard, Suite 221, South San Francisco Ca 94080.

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App 中文

Education

Financial Glossary Tutorials FAQ Schedule Free Session Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Site Map Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.